Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Haemophiliacs and their treatment – danger signals involved in immune response against factor-VIII

28.03.2018

In patients with haemophilia A, the missing blood coagulation factor VIII is administered, and thus replaced, intravenously. A part of the patients, however, develops antibodies (inhibitors) against factor VIII, which, in the worst case scenario, can cause uncontrolled bleeding. Researchers of the Paul-Ehrlich-Institut (PEI) have now established that the adverse immune reactions occur in the presence of so-called danger signals. After antigen processing, mainly memory T cells are activated. The results are published in Thromb. Haemost. in its online edition of 19 March 2018.

Haemophilia A is the most common congenital blood coagulation disorder. It is caused by various mutations in the so-called factor VIII (F8) gene. Depending on the type of mutation, the coagulation factor VIII is not formed in sufficient quantities or is missing entirely.


Photographic image taken under an electron microscope: Red blood cells, leukocytes and platelets

National Cancer Institute

The missing coagulation factor is replaced by intravenous administration of so-called factor-VIII concentrates. However, around a quarter of treated patients who have severe haemophilia develop antibodies against factor VIII – the body treats the coagulations factor like a foreign body and inactivates it using its immune system.

One essential risk factor for the development of these inhibitors is a pronounced F8 mutation. However, not all patients who have such a mutation develop inhibitors, and, vice versa, inhibitors can also be found in a part of the patients with only minor alterations of the F8 gene. What complicates understanding the underlying mechanisms even more is that antibodies against factor VIII can be detected in some healthy individuals, too.

Inhibitors against factor-VIII concentrates partly make treatments of the patients concerned very difficult, and in extreme cases, they can lead to uncontrollable bleedings. For this reason, the team of scientists of Dr Zoe Waibler, head of Section Product Testing of Immunological Biomedicines of the Division Immunology at the Paul-Ehrlich-Institut has performed research on the underlying mechanisms in search of a possibility to prevent the formation of these inhibitors.

In previous research activities, she and her team had shown that certain “danger signals” in the blood such as particular surface molecules of bacteria (LPS, lipopolysaccharides) that warn the body of a pathogenic agent will increase the immunogenicity of factor-VIII products [1]. Immunogenicity describes the ability of molecules to elicit an immune reaction. Another example of this is cell stress resulting from surgical intervention, which transmits danger signals by releasing particular substances.

The increased immunogenicity of factor-VIII products causes so-called dendritic cells (DCs) to be activated to an increasing extent. These immune cells present antigens on their surface, i.e. molecular structures against which an immune response can be mediated. They form part of the innate immune system. In connection with other molecules, this leads to the formation of a subgroup of immune cells of the acquired immune system, the CD4-positive T cells, which are also called T helper cells.

Waibler’s team was now able to show that DCs, which are activated by the factor-VIII concentrate and the danger signal LPS synergistically, mediate a considerably stronger T helper cell activation than DCs, which were pre-treated solely with either factor VIII or LPS alone. In addition, they were able to clarify the dependency of T-cell activation on further immunological processing steps.

“Our results are another step on the road towards clarifying these complex immunological processes. This is a prerequisite for developing new approaches to haemophilia therapies which prevent the formation of these inhibitors against factor-VIII products”, said Waibler when explaining the significance of the results.

1. Miller L et al.: Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products. Thromb Haemost. 2015 Aug;114(2):268-76

Original publication:
(DOI:)

Miller L, Ringler E, Kistner KM, Waibler Z; ABIRISK Consortium (2017): Human dendritic cells synergistically activated by FVIII plus LPS induce activation of autologous CD4+ T cells. Thromb Haemost. 2018 Mar 19. doi: 10.1055/s-0038-1637734

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute. The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen:

https://www.ncbi.nlm.nih.gov/pubmed/?term=Human+dendritic+cells+synergistically+... - Abstract
https://www.pei.de/EN/information/journalists-press/press-releases/2018/05-haemo... press release

Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View
22.06.2018 | University of Sussex

nachricht New cellular pathway helps explain how inflammation leads to artery disease
22.06.2018 | Cedars-Sinai Medical Center

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>